Penumbra, Inc.Long
Penumbra: Richly-valued but trades well after earnings
Nov 5th, 3:12 pm
PEN Q3 top line beat of 111.8M vs consensus 102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for 
JNJ 
MDT or even 
EW
Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
PEN Q3 top line beat of 111.8M vs consensus 102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38MNov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for JNJ MDT or even EWWells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.